Larimar advances nomlabofusp toward accelerated Friedreich’s ataxia approval

An update from Larimar Therapeutics ( (LRMR) ) is now available.

On January 12, 2026, Larimar Therapeutics posted an updated corporate slide deck outlining the progress of its lead candidate nomlabofusp toward registration as what it positions as the first potential disease-modifying therapy for Friedreich’s ataxia, supported by data from four completed clinical studies plus an ongoing open-label trial showing dose-dependent increases in tissue frataxin. The materials emphasize strong clinician demand for frataxin-targeted treatments, the company’s strategy to pursue accelerated U.S. approval using frataxin levels as a novel surrogate endpoint with key regulatory milestones anticipated in 2026 and a potential U.S. launch in early 2027, and an extensive intellectual property portfolio and market exclusivity framework that, if approval is obtained, could secure a long runway of protection for nomlabofusp in the U.S. and Europe, reinforcing Larimar’s competitive position in this rare-disease niche.

The most recent analyst rating on (LRMR) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Larimar Therapeutics stock, see the LRMR Stock Forecast page.

Spark’s Take on LRMR Stock

According to Spark, TipRanks’ AI Analyst, LRMR is a Neutral.

The score is held down primarily by weak financial performance (no revenue, widening losses, and significant cash burn), partially offset by a low-debt balance sheet. Technical indicators are moderately positive, but valuation support is limited due to negative earnings and no dividend.

To see Spark’s full report on LRMR stock, click here.

More about Larimar Therapeutics

Larimar Therapeutics is a biotechnology company focused on developing nomlabofusp (CTI-1601), a first-in-class mitochondrial protein replacement therapy intended to address systemic frataxin deficiency in patients with Friedreich’s ataxia (FA), a rare, progressive neurodegenerative disease affecting roughly 20,000 people worldwide and around 5,000 in the U.S. The company targets high unmet medical need in FA, where the only currently approved therapy does not correct frataxin deficiency, and holds multiple regulatory designations across the U.S. and Europe as well as a patent estate that extends composition-of-matter protection for nomlabofusp into 2040.

Average Trading Volume: 1,454,392

Technical Sentiment Signal: Sell

Current Market Cap: $287.6M

For an in-depth examination of LRMR stock, go to TipRanks’ Overview page.